Rescuing the Brain on Fire with Membrane Medicine
Membrane Medicine is a targeted neurometabolic approach for neurological disorders including autism, seizures, pervasive developmental delay (PDD), and mitochondrial using bioactive lipid therapy. Our research consortium has found that epigenetic insult drives the clinical course of neurological disorders, including autism spectrum disorder, resulting in disturbed organelle interplay, unfolded protein and cell danger response, the formation of aberrant proteins (misfolded, aggregated, unfolded) and lipids (VLCFAs, ceramides, deranged conformations, damaged) that may be attenuated with bioactive lipids and chaperones. Progression of autism, seizures and PDD are hallmarked by impaired peroxisomal and mitochondrial respiration and phospholipid instability due to altered gene expression following toxic exposure. Phospholipid and bioactive lipid therapy can be utilized to clear nuclear and mitochondria DNA adducts resulting from toxic exposure to chemicals, fungus, metals, pesticides and microbials to reverse altered gene expression and optimize membrane function. Therapeutic modalities include targeted bioactive lipids with phospholipids, SR3 oil, linoleic acid, gamma linoleic acid, caviar, stimulation of resolvins/protectins/maresins with butyrate/phenylbutyrate, and a membrane-stabilizing diet. The Membrane Stabilizing approach is supportive to optimizing cellular brain architecture, organelle and cell membranes to address epigenetic-induced neurological challenges and the ‘Brain on Fire.’ Our optimization of membrane and neurometabolic function with the use of targeted bioactive lipids, utilized both orally and intravenously, has has yielded marked clinical neurological improvement in patients over the past 21 years following 3 months of a targeted phospholipid regime corresponding with significant normalization in red cell lipid analysis, cardiolipin, peroxisomal/mitochondrial respiration, epigenetic status, cellular structure, cell leaflets, and membrane phospholipid arrangement.
Patricia C. Kane, PhD
Patricia Kane, PhD, serves as Director of the NeuroLipid Research Foundation, a 501c3 nonprofit organization in Millville,New Jersey. Her expertise in addressing neurological, genetic and epigenetic disorders with targeted bioactive lipid intervention has led to direct neurometabolic application utilized by physicians and researchers worldwide. Dr. Kane's clinical experience, working as a 'living library' for physicians, spans 39 years. She pioneered targeted neurometabolic application of university based red cell fatty acid analysis for the past 21 years. In 2008, she applied a specialized epigenetic analysis ‘a portal into the cell’ whereby images of the membrane surface, phospholipids and mitochondria of each patient along with their DNA adducts were utilized to approach the patient’s epigenetic aberrations. Dr. Kane’s work has expedited the incorporation of current research and evidence based medicine directly into clinical practice to yield resolution of some of the complex medical disorders of our time.Dr. Kane's dedication and success in working with patients with fragile brain architecture has brought her widespread recognition in the field of biometabolic intervention by blending lipid bench science and medical lipid research with clinical medicine.
Carolyn Matzinger, MD
Dr. Carolyn Matzinger’s career began in 1987 upon receiving her Medical Degree from Wright State University School of Medicine. Completing her Internal Medicine Residency Program in 1990 at the Kettering Medical Center in Kettering, Ohio provided a solid basis for Dr. Matzinger’s study in Internal Medicine followed by Anti-Aging, Regenerative and Functional Medicine. As a Diplomate of both the American Board of Internal Medicine and the American Board of Anti-Aging Medicine, she has worked diligently to be at the forefront of her specialty. She is currently licensed in five states including; Nevada, California, Ohio, Idaho, and Montana.
